Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer

Journal of Receptors and Signal Transduction

Volumn 32, Issue 6, 2012, Pages 321-327

  Singh, Neha ^a   Hussain, Showket ^b   Bharadwaj, Mausumi ^b   Kakkar, Nandita ^c   Singh, S K ^c   Sobti, Ranbir C ^a  

^a PANJAB UNIVERSITY   (India)

^b Institute of Cytology and Preventive Oncology ICMR   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Prostate cancer; SOCS 1; STAT 3; STAT 5

Indexed keywords

JANUS KINASE; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TISSUE SECTION; TRANSURETHRAL RESECTION;

AGED; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84870544140     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2012.733885     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61, 69-90.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61, 1079-1092.
3. Yeole BB. Trends in the prostate cancer incidence in India. Asian Pac J Cancer Prev 2008, 9, 141-144.
4. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003, 361, 955-964.
5. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7, 64.
6. Karayi MK, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis 2004, 7, 6-20.
7. Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer 2001, 1, 34-45.
8. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001, 61, 4683-4688.
9. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999, 53, 707-713.
10. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996, 27, 668-675.
11. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4, 97-105.
12. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 2000, 25, 496-502.
13. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19, 2474-2488.
14. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19, 2468-2473.
15. Sobti RC, Kumari M, Sharma VL, Sodhi M, Mukesh M, Shouche Y. Sequence analysis of a few species of termites (Order: Isoptera) on the basis of partial characterization of COII gene. Mol Cell Biochem 2009, 331, 145-151.
16. Sobti RC, Singh N, Hussain S, Suri V, Bharadwaj M, Das BC. Deregulation of STAT-5 isoforms in the development of HPVmediated cervical carcinogenesis. J Recept Signal Transduct Res 2010, 30, 178-188.
17. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P, de Sepulveda P. The tumor suppressor activity of SOCS-1. Oncogene 2002, 21, 4351-4362.
18. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001, 28, 29-35.
19. Hussain S, Singh N, Salam I, Bandil K, Yuvaraj M, Akbar Bhat M, Muzaffar Mir M, Siddiqi MA, Sobti RC, Bharadwaj M, Das BC. Methylation-mediated gene silencing of suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal squamous cell carcinoma patients of Kashmir valley. J Recept Signal Transduct Res 2011, 31, 147-156.
20. Sobti RC, Singh N, Hussain S, Suri V, Nijhawan R, Bharti AC, Bharadwaj M, Das BC. Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol (Dordr) 2011, 34, 533-543.
21. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007, 97, 378-383.
22. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7, 41-51.
23. Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003, 197, 157-168.
24. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT-3. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2009, 9, 798-809.
25. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT-3. Nat Rev Cancer 2009, 9, 798-809.
26. Park OK, Schaefer TS, Nathans D. In vitro activation of STAT-3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA 1996, 93, 13704-13708.
27. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117, 3846-3856.
28. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003, 63, 2948-2956.
29. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000, 21, 427-433.
30. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008, 68, 236-248.
31. Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol 2009, 174, 1921-1930.
32. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgenmediated proliferation and secretion. Endocr Relat Cancer 2007, 14, 1007-1019.
33. Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, Sawaya R, Huang S. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 2008, 68, 9634-9642.